<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6  ADVERSE REACTIONS<BR>               <BR>                  The following risks are discussed in greater detail in other sections of the labeling: <BR>                  <BR>                     Depression and suicidality [see <BR>                        <BR>                           Warnings and Precautions (5.3)]<BR>                     <BR>                     Akathisia, restlessness and agitation [see <BR>                        <BR>                           Warnings and Precautions (5.6)]<BR>                     <BR>                     Parkinsonism [see <BR>                        <BR>                           Warnings and Precautions (5.7)]<BR>                     <BR>                     Sedation and somnolence [see <BR>                        <BR>                           Warnings and Precautions (5.9)]<BR>                     <BR>                     Dysphagia [see <BR>                        <BR>                           Warnings and Precautions (5.8)]<BR>                     <BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        The most common adverse reactions are (>10% and at least 5% greater than placebo):  Sedation/somnolence, fatigue, insomnia, depression, akathisia, anxiety, nausea. (6)<BR>                        <BR><BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact XENAZINE Information Center at 1-888-882-6013 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<BR>                           .<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1   Commonly Observed Adverse Reactions in Controlled Clinical Trials<BR>                     <BR>                        The most common adverse reactions from Table 1 occurring in over 10% of XENAZINE-treated patients, and at least 5% greater than placebo, were sedation/somnolence (31%), fatigue (22%), insomnia (22%), depression (19%), akathisia (19%), and nausea (13%).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2   Clinical Studies Experience<BR>                     <BR>                        Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<BR>                        During its development, XENAZINE was administered to 773 unique subjects and patients. The conditions and duration of exposure to XENAZINE varied greatly, and included single and multiple dose clinical pharmacology studies in healthy volunteers (n=259) and open-label (n=529) and double-blind studies (n=84) in patients.<BR>                        In a randomized, 12-week, placebo-controlled clinical trial of HD subjects, adverse reactions (ARs) were more common in the XENAZINE group than in the placebo group.  Forty-nine of 54 (91%) patients who received XENAZINE experienced one or more ARs at any time during the study. The ARs most commonly reported (over 10%, and at least 5% greater than placebo) were sedation/somnolence (31% vs. 3% on placebo), fatigue (22% vs. 13% on placebo), insomnia (22% vs. 0% on placebo), depression (19% vs. 0% on placebo), akathisia (19% vs. 0% on placebo), and nausea (13% vs. 7% on placebo).<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Adverse Reactions Occurring in ≥4% Patients              <BR>                              <BR>                              The number and percentage of the most commonly reported AEs that occurred at any time during the study in ≥4% of XENAZINE-treated patients, and with a greater frequency than in placebo-treated patients, are presented in Table 1 in decreasing order of frequency within body systems for the XENAZINE group.<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="85%"><BR>                                 <caption>Table 1.  Treatment Emergent Adverse Reactions in Patients Treated with XENAZINE and with a Greater Frequency than Placebo in the 12-Week, Double-Blind, Placebo-Controlled Trial of XENAZINE</caption><BR>                                 <col width="30" align="left" valign="top"/><BR>                                 <col width="30" align="left" valign="top"/><BR>                                 <col width="20" align="center" valign="top"/><BR>                                 <col width="20" align="center" valign="top"/><BR>                                 <thead><BR>                                    <tr><BR>                                       <th styleCode="Lrule Rrule" align="center">Body System</th><BR>                                       <th styleCode="Rrule" align="center">AE Term</th><BR>                                       <th styleCode="Rrule">XENAZINE<br/>n = 54<br/>n (%)</th><BR>                                       <th styleCode="Rrule">Placebo<br/>n = 30<br/>n (%)</th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="7">PSYCHIATRIC DISORDERS</td><BR>                                       <td styleCode="Rrule">Sedation/somnolence</td><BR>                                       <td styleCode="Rrule">17 (31%)</td><BR>                                       <td styleCode="Rrule">1 (3%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Insomnia</td><BR>                                       <td styleCode="Rrule" align="center">12 (22%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Depression</td><BR>                                       <td styleCode="Rrule" align="center">10 (19%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Anxiety/anxiety aggravated</td><BR>                                       <td styleCode="Rrule" align="center">8 (15%)</td><BR>                                       <td styleCode="Rrule">1 (3%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Irritability</td><BR>                                       <td styleCode="Rrule" align="center">5 (9%)</td><BR>                                       <td styleCode="Rrule">1 (3%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Appetite decreased</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Obsessive reaction</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="7">CENTRAL &amp; PERIPHERAL NERVOUS SYSTEM</td><BR>                                       <td styleCode="Rrule">Akathisia</td><BR>                                       <td styleCode="Rrule">10 (19%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Balance difficulty</td><BR>                                       <td styleCode="Rrule" align="center">5 (9%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Parkinsonism/bradykinesia</td><BR>                                       <td styleCode="Rrule" align="center">5 (9%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Dizziness</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Dysarthria</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Gait unsteady</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Headache</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">1 (3%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">GASTROINTESTINAL SYSTEM DISORDERS</td><BR>                                       <td styleCode="Rrule">Nausea</td><BR>                                       <td styleCode="Rrule">7 (13%)</td><BR>                                       <td styleCode="Rrule">2 (7%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Vomiting</td><BR>                                       <td styleCode="Rrule" align="center">3 (6%)</td><BR>                                       <td styleCode="Rrule">1 (3%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="4"><BR>                                          <br/>BODY AS A WHOLE &#8211; GENERAL</td><BR>                                       <td styleCode="Rrule">Fatigue</td><BR>                                       <td styleCode="Rrule">12 (22%)</td><BR>                                       <td styleCode="Rrule">4 (13%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Fall</td><BR>                                       <td styleCode="Rrule" align="center">8 (15%)</td><BR>                                       <td styleCode="Rrule">4 (13%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Laceration (head)</td><BR>                                       <td styleCode="Rrule" align="center">3 (6%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Ecchymosis</td><BR>                                       <td styleCode="Rrule" align="center">3 (6%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="3">RESPIRATORY SYSTEM DISORDERS</td><BR>                                       <td styleCode="Rrule">Upper respiratory tract infection</td><BR>                                       <td styleCode="Rrule">6 (11%)</td><BR>                                       <td styleCode="Rrule">2 (7%)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Shortness of breath</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">Bronchitis</td><BR>                                       <td styleCode="Rrule" align="center">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Lrule Rrule">URINARY SYSTEM DISORDERS</td><BR>                                       <td styleCode="Rrule">Dysuria</td><BR>                                       <td styleCode="Rrule">2 (4%)</td><BR>                                       <td styleCode="Rrule">-</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR>Dose escalation was discontinued or dosage of study drug was reduced because of one or more ARs in 28 of 54 (52%) patients randomized to XENAZINE.  These ARs consisted of sedation (15), akathisia (7), parkinsonism (4), depression (3), anxiety (2), fatigue (1) and diarrhea (1). Some patients had more than one AR and are, therefore, counted more than once.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Adverse Reactions Due to Extrapyramidal Symptoms (EPS)           <BR>                              <BR>                              The following table describes the incidence of events considered to be extrapyramidal adverse reactions.<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="65%"><BR>                                 <caption>Table 2. Treatment Emergent EPS in Patients Treated with XENAZINE occurring with a Greater Frequency than Placebo in the 12-Week, Double-Blind, Placebo-Controlled Trial of  XENAZINE</caption><BR>                                 <col width="40%" align="left" valign="bottom"/><BR>                                 <col width="40%" align="center" valign="top"/><BR>                                 <col width="20%" align="center" valign="top"/><BR>                                 <thead><BR>                                    <tr><BR>                                       <th styleCode="Lrule Rrule" rowspan="2">Event</th><BR>                                       <th styleCode="Rrule Botrule" colspan="2" align="left">Patients (%) reporting event</th><BR>                                    </tr><BR>                                    <tr><BR>                                       <th styleCode="Rrule" align="center">XENAZINE<br/>n = 54</th><BR>                                       <th styleCode="Rrule">Placebo<br/>n = 30</th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Akathisia <footnote>Patients with the following adverse event preferred terms were counted in this category: akathisia, hyperkinesia, restlessness.</footnote><BR>                                       </td><BR>                                       <td styleCode="Rrule">10 (19%)</td><BR>                                       <td styleCode="Rrule">0</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Extrapyramidal event <footnote>Patients with the following adverse event preferred terms were counted in this category: bradykinesia, parkinsonism, extrapyramidal disorder, hypertonia. </footnote><BR>                                       </td><BR>                                       <td styleCode="Rrule">8 (15%)</td><BR>                                       <td styleCode="Rrule">0</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Lrule Rrule">Any extrapyramidal event</td><BR>                                       <td styleCode="Rrule">18 (33%)</td><BR>                                       <td styleCode="Rrule">0</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR>Patients may have had events in more than one category.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.3   Laboratory Tests<BR>                     <BR>                        No clinically significant changes in laboratory parameters were reported in clinical trials with XENAZINE.  In controlled clinical trials, XENAZINE caused a small mean increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), laboratory values as compared to placebo.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.4   Vital Signs<BR>                     <BR>                        In controlled clinical trials, XENAZINE did not affect blood pressure, pulse, and body weight.  Orthostatic blood pressure was not consistently measured in the XENAZINE clinical trials.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>